Dose-dense chemotherapy has been proposed to improve breast cancer outcome due to its ability to prevent cancer cell repopulation; however, little is known about which patients benefit most from such scheduling. A pooled analysis of studies assessing dose-dense adjuvant chemotherapy has shown that most of the therapeutic benefit derived from dose-dense scheduling arises in patients with node-positive, triple-negative disease.
This is a preview of subscription content, log in via an institution to check access.
References
Bonadonna, G. et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294, 405–410 (1976).
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).
De Laurentiis, M. et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26, 44–53 (2008).
Citron, M. L. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431–1439 (2003).
Sparano Joseph, A. et al. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. N. Engl. J. Med. 358, 1663–1671 (2008).
Venturini, M. et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J. Natl Cancer Inst. 97, 1724–1733 (2005).
Berry, D. A. et al. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA 295, 1658–1667 (2006).
Norton, L. & Simon, R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 61, 1307–1317 (1977).
Del Mastro, L. et al. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br. J. Cancer 93, 7–14 (2005).
Dang, C. et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J. Clin. Oncol. 26, 1216–1222 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Amir, E., Ocana, A., Freedman, O. et al. Dose-dense treatment for triple-negative breast cancer. Nat Rev Clin Oncol 7, 79–80 (2010). https://doi.org/10.1038/nrclinonc.2009.231
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.231
- Springer Nature Limited
This article is cited by
-
Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT)
Breast Cancer Research and Treatment (2019)
-
Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis
Breast Cancer Research and Treatment (2018)
-
Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients
Supportive Care in Cancer (2017)
-
Lectin RCA-I specifically binds to metastasis-associated cell surface glycans in triple-negative breast cancer
Breast Cancer Research (2015)
-
FZD7 has a critical role in cell proliferation in triple negative breast cancer
Oncogene (2011)